2022 Revenues ($USD) : $3,983,680,000 2022 Revenues (foreign currencies) : € 3,376,000,000 2022 R&D spend : $459,020,000 2022 Number of Employees : 13,000 Fiscal Year End : 12/31/2021 Company CEO : Alexandre Mérieux, CEO and chair
An important player in the in vitro diagnostics space for more than 55 years, BioMérieux has a presence in 44 countries and serves more than 160 countries with the support of large distributors. The company provides a wide range of diagnostic systems, reagents, software and services to detect diseases and contamination, improve people’s health and bolster consumer safety. An upturn in U.S. respiratory panels demand amid the COVID-19 Delta variant wave pushed sales up 10.5% in 2021. In 2022, BioMérieux purchased San Jose, California-based Specific Diagnostics, and later launched Aurobac Therapeutics, a joint venture with Boehringer Ingelheim and Evotec to fight antimicrobial resistance. Most recently, the FDA granted Breakthrough Device Designation to BioMérieux’s Specific Reveal Rapid Antimicrobial Susceptibility Test System. –CN and JH